Uncategorized
Aerpio Pharmaceuticals to Present Data Demonstrating Role of VE-PTP in Conventional Outflow Homeostasis and the Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, as a Treatment for Open-Angle Glaucoma
CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, will present data demonstrating the role of VE-PTP in the conventional outflow pathway and the potential of AKB-9778, a VE-PTP inhibitor and Tie2 activator, as a treatment for open-angle-glaucoma. The data are to be presented at The Association for Research in Vision and Ophthalmology (ARVO) 2